These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

648 related articles for article (PubMed ID: 34473462)

  • 21. Evaluation of the Safety and Efficacy of Avacopan, a C5a Receptor Inhibitor, in Patients With Antineutrophil Cytoplasmic Antibody-Associated Vasculitis Treated Concomitantly With Rituximab or Cyclophosphamide/Azathioprine: Protocol for a Randomized, Double-Blind, Active-Controlled, Phase 3 Trial.
    Merkel PA; Jayne DR; Wang C; Hillson J; Bekker P
    JMIR Res Protoc; 2020 Apr; 9(4):e16664. PubMed ID: 32088663
    [TBL] [Abstract][Full Text] [Related]  

  • 22. The evolving treatment of ANCA-associated vasculitides.
    Sauranen J; Salmela A; Kahlos K; Antonen J; Ekstrand A; Pettersson T
    Duodecim; 2016; 132(16):1449-55. PubMed ID: 29188932
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Mycophenolate Mofetil Versus Cyclophosphamide for the Induction of Remission in Nonlife-Threatening Relapses of Antineutrophil Cytoplasmic Antibody-Associated Vasculitis: Randomized, Controlled Trial.
    Tuin J; Stassen PM; Bogdan DI; Broekroelofs J; van Paassen P; Cohen Tervaert JW; Sanders JS; Stegeman CA
    Clin J Am Soc Nephrol; 2019 Jul; 14(7):1021-1028. PubMed ID: 31253599
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Avacopan, a Novel Competitive C5a Receptor Antagonist, for Severe Antineutrophil Cytoplasmic Autoantibody-Associated Vasculitis.
    Nguyen ID; Sinnathamby ES; Mason J; Urban B; Neuchat EE; Wenger DM; Ahmadzadeh S; Shekoohi S; Kaye AD
    Clin Drug Investig; 2023 Aug; 43(8):595-603. PubMed ID: 37596445
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Evaluation of Rituximab for Induction and Maintenance Therapy in Patients 75 Years and Older With Antineutrophil Cytoplasmic Antibody-Associated Vasculitis.
    Thietart S; Karras A; Augusto JF; Philipponnet C; Carron PL; Delbrel X; Mesbah R; Blaison G; Duffau P; El Karoui K; Smets P; London J; Mouthon L; Guillevin L; Terrier B; Puéchal X;
    JAMA Netw Open; 2022 Jul; 5(7):e2220925. PubMed ID: 35802372
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Saint John on Patmos: Revelations of the Role of Antineutrophil Cytoplasmic Antibody (ANCA) in Vasculitis.
    Pijnappel EN; Rijkers GT; Overveld FJV
    Curr Med Chem; 2020; 27(17):2852-2862. PubMed ID: 31838986
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Rituximab versus cyclophosphamide in ANCA-associated renal vasculitis.
    Jones RB; Tervaert JW; Hauser T; Luqmani R; Morgan MD; Peh CA; Savage CO; Segelmark M; Tesar V; van Paassen P; Walsh D; Walsh M; Westman K; Jayne DR;
    N Engl J Med; 2010 Jul; 363(3):211-20. PubMed ID: 20647198
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Complement Inhibition in ANCA-Associated Vasculitis.
    Tesar V; Hruskova Z
    Front Immunol; 2022; 13():888816. PubMed ID: 35880179
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Management of primary vasculitides with biologic and novel small molecule medications.
    Serling-Boyd N; Wallace ZS
    Curr Opin Rheumatol; 2021 Jan; 33(1):8-14. PubMed ID: 33164993
    [TBL] [Abstract][Full Text] [Related]  

  • 30. AVACOPAN: A New Adjunctive Therapy for Antineutrophil Cytoplasmic Antibody-Associated Vasculitis.
    Garg J; Frishman WH
    Cardiol Rev; 2023 Jan-Feb 01; 31(1):3-6. PubMed ID: 36469359
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Plasma levels of soluble interleukin 2 receptor, soluble CD30, interleukin 10 and B cell activator of the tumour necrosis factor family during follow-up in vasculitis associated with proteinase 3-antineutrophil cytoplasmic antibodies: associations with disease activity and relapse.
    Sanders JS; Huitma MG; Kallenberg CG; Stegeman CA
    Ann Rheum Dis; 2006 Nov; 65(11):1484-9. PubMed ID: 16504995
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Efficacy and safety of avacopan in patients with ANCA-associated vasculitis receiving rituximab in a randomised trial.
    Geetha D; Dua A; Yue H; Springer J; Salvarani C; Jayne D; Merkel P;
    Ann Rheum Dis; 2024 Jan; 83(2):223-232. PubMed ID: 37979959
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Evaluation of PR3-ANCA Status After Rituximab for ANCA-Associated Vasculitis.
    McClure ME; Wason J; Gopaluni S; Tieu J; Smith RM; Jayne DR; Jones RB
    J Clin Rheumatol; 2019 Aug; 25(5):217-223. PubMed ID: 30896460
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Rituximab versus azathioprine for maintenance in ANCA-associated vasculitis.
    Guillevin L; Pagnoux C; Karras A; Khouatra C; Aumaître O; Cohen P; Maurier F; Decaux O; Ninet J; Gobert P; Quémeneur T; Blanchard-Delaunay C; Godmer P; Puéchal X; Carron PL; Hatron PY; Limal N; Hamidou M; Ducret M; Daugas E; Papo T; Bonnotte B; Mahr A; Ravaud P; Mouthon L;
    N Engl J Med; 2014 Nov; 371(19):1771-80. PubMed ID: 25372085
    [TBL] [Abstract][Full Text] [Related]  

  • 35. ANCA-associated vasculitides: advances in pathophysiology and treatment.
    Erwig LP; Savage CO
    Neth J Med; 2010 Feb; 68(2):62-7. PubMed ID: 20167957
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Pathogenesis and treatment of ANCA-associated vasculitides.
    Kallenberg CG
    Clin Exp Rheumatol; 2015; 33(4 Suppl 92):S11-4. PubMed ID: 26457917
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Current landscape of antineutrophil cytoplasmic antibody-associated vasculitis: classification, diagnosis, and treatment.
    Lally L; Spiera R
    Rheum Dis Clin North Am; 2015; 41(1):1-19, vii. PubMed ID: 25399936
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Systematic review and meta-analysis for 2023 clinical practice guidelines of the Japan Research Committee of the Ministry of Health, Labour, and Welfare for Intractable Vasculitis for the management of ANCA-associated vasculitis.
    Watanabe R; Oshima M; Nishioka N; Sada KE; Nagasaka K; Akiyama M; Ando T; Higuchi T; Inoue Y; Kida T; Mutoh T; Nakabayashi A; Onishi A; Sakai R; Waki D; Yamada Y; Yajima N; Tamura N; Kaname S; Harigai M
    Mod Rheumatol; 2023 Aug; 33(5):982-989. PubMed ID: 36112482
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Antineutrophil Cytoplasmic Antibody-Associated Vasculitis: Toward an Individualized Approach.
    Villacorta J; Martinez-Valenzuela L; Martin-Capon I; Bordignon-Draibe J
    Nephron; 2022; 146(2):121-137. PubMed ID: 34915506
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Hypertrophic pachymeningitis in ANCA-associated vasculitis: Clinical and immunopathological features and insights.
    Shimojima Y; Sekijima Y
    Autoimmun Rev; 2023 Jun; 22(6):103338. PubMed ID: 37062439
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 33.